Fri 1/19/2018 20:02 ET
DJIA26071.7253.910.21%SOLAR25.970.010.04%GOLD1331.103.860.29%Shanghai3487.2412.550.36%
S&P 5002810.3012.370.44%BANKS29.540.210.71%OIL63.570.380.60%BITCOIN11586.0464.880.56%
NASDAQ7336.3840.350.55%SEMI106.770.100.09%US/EU1.220.000.00%Futures2812.7516.500.59%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Aviron - AVIR   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add AVIR
  
From: Mores (Rep: 3)Date: 01/12/2018 13:40
Forum: Aviron - Msg #137Thread #673982117 (Rec: 0)
The transaction maximizes the value of Aviragen: Based on the valuations of a selected set of publicly traded vaccine companies, Vaxart’s estimated potential valuation prior to the merger is approximately $158 million. Based on the ownership structure in the transaction, this would imply a value of the combined company at $264 million, with the potential value of Aviragen in the merger being $106 million, a significant improvement in value compared to Aviragen’s current market capitalization of approximately $23 millioni.

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser Mores: Reward | Watch | IgnoreAVIR: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add AVIR
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.